Zooming in on protein to
prevent kidney stones
Researchers have applied
Nobel prize-winning microscope technology to uncover an ion channel structure
that could lead to new treatments for kidney stones. In a recent study
published in Nature Structural and Molecular Biology, researchers
revealed atomic-level details of the protein that serves as a passageway for
calcium across kidney cell membranes.
Approximately 80 percent of kidney stones are comprised of calcium salts. They are extremely painful to pass, and depending on size and location can require surgery to remove. Ion channels that span kidney cell membranes help reabsorb calcium from the urine before it can form kidney stones.
The new study is the first to show molecular
details of the essential kidney calcium channel, called TRPV5, in its closed
form. The study also reveals how inhibitor molecules attach to and close the
channel, leaving calcium stranded in the urine where it can form kidney stones.
"Now that we know what the protein looks
like in its inhibited state, drugs can be made with the intention of modulating
TRPV5 activity and potentially treating kidney stones directly," said
first author Taylor Hughes, PhD candidate in the Department of Pharmacology at
Case Western Reserve University School of Medicine.
In the new study, Hughes and colleagues used
a technique called cryo-electron microscopy—that won the 2017 Nobel prize in
Chemistry—to view rabbit TRPV5 attached to its inhibitor molecule, econazole.
Cryo-electron microscopy enabled the researchers to zoom in and see protein
structures in atomic details. From the new vantage point they could identify
different protein regions, including the portion that crosses kidney cell
membranes, and attachment sites for molecules like econazole.
"When performing cryo-electron
microscopy, we shoot electrons at our frozen protein and it allows us to take
pictures of individual protein molecules. With these pictures and advanced
computer software we are able to create 3D models of these molecules. These 3D
models have the potential to be so precise that we can actually see the atoms
that make up the protein," Hughes explained.
The 3D models helped the researchers predict
how TRPV5 opens and closes for the first time. "To understand how a
protein moves we need multiple structures to compare to one another,"
Hughes said. "We were able to draw conclusions about the mechanisms of
action by comparing our inhibitor-bound structure to a previously published
TRPV6 structure solved without an inhibitor.
TRPV5 and TRPV6 are part of the same
subfamily of proteins and very similar in sequence as well as structure."
The new research builds upon experiments performed by Tibor Rohacs, MD, PhD, at
Rutgers New Jersey Medical School and computations by Marta Filizola, PhD at
Icahn School of Medicine at Mount Sinai.
The researchers viewed TRPV5-econazole
complexes under the 12-foot tall cryo-electron microscope housed at the
Electron Imaging Center for NanoMachines in the California NanoSystems
Institute at University of California Los Angeles. Vera Moiseenkova-Bell, PhD,
senior author on the study, has access to this facility as a member of the
West/Midwest consortium for high-resolution cryo-electron microscopy supported
by the National Institutes of Health. The study also brought together other
researchers from Case Western Reserve University, University of California Los
Angeles, Rutgers University, Icahn School of Medicine at Mount Sinai, and
Pfizer. Moiseenkova-Bell is a Mount Sinai Scholar and former Associate
Professor of Pharmacology at Case Western Reserve University School of
Medicine.
"This publication is the first time the
structure of TRPV5 has been solved. Now, structures for four of the six TRPV
subfamily members are available at near-atomic resolution for further
scientific investigation," Hughes said. According to the researchers,
future studies could include targeted therapies to modulate the protein
channels in people suffering from kidney stones.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.